Abstract：
:The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT activation may result from genetic hits affecting different components of the pathway, whereas the mechanisms leading to constitutive mTORC1 activation remain globally unknown. The connections between the PI3K and mTOR kinases are multiple and complex, including common substrates, negative feedback loops, or direct activation mechanisms. First-generation allosteric mTOR inhibitors (eg, rapamycin) are mainly active on mTORC1 and mostly display cytostatic anti-tumor activity. Recently, second-generation catalytic mTOR inhibitors targeting both mTOR complexes 1 and 2 have been developed. Some of them also inhibit class IA PI3K. Here, we highlight recent data generated with these new inhibitors against cancer cells and their potential as anti-cancer drugs.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Willems L,Tamburini J,Chapuis N,Lacombe C,Mayeux P,Bouscary Ddoi
10.1007/s11912-012-0227-ysubject
Has Abstractpub_date
2012-04-01 00:00:00pages
129-38issue
2eissn
1523-3790issn
1534-6269journal_volume
14pub_type
杂志文章,评审abstract：PURPOSE OF REVIEW:Standard treatment for early-stage squamous cell cancer of the anal canal (SCCA) includes concurrent chemotherapy and radiation to achieve curative intent. Treatment options are limited, however, especially with locoregional disease relapse occurring in 20-30% of patients and about 10-30% of patients ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00946-3
更新日期：2020-07-11 00:00:00
abstract：:Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor pr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0680-3
更新日期：2018-04-02 00:00:00
abstract：:Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described. The KIT gene is commonly mutated, causing constitutive activation of the protein and a...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-003-0068-9
更新日期：2003-07-01 00:00:00
abstract：:The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discover...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0015-5
更新日期：2009-03-01 00:00:00
abstract：:Lymphoma is the third most common cancer in children and adolescents. Non-Hodgkin's lymphomas comprise a heterogeneous group of tumors with distinct pathologic and clinical characteristics. Over the past three decades, significant advancements have been made in the molecular characterization of these disorders. With t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0062-0
更新日期：2006-09-01 00:00:00
abstract：:Health-related quality of life (QOL) outcomes are frequently used by clinicians, patients, and researchers for assessing the effectiveness of an intervention. Small differences in QOL may be statistically significant but their clinical relevance remains undefined. The smallest changes in QOL scores of the anterior sku...
journal_title：Current oncology reports
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11912-012-0222-3
更新日期：2012-04-01 00:00:00
abstract：:In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0058-0
更新日期：2000-09-01 00:00:00
abstract：:New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and pa...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-005-0073-2
更新日期：2005-05-01 00:00:00
abstract：:Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0008-9
更新日期：2008-01-01 00:00:00
abstract：:While there is an ongoing debate regarding the timing of the maximal surgical effort in epithelial ovarian cancer, it is well established that patients with suboptimal tumor debulking derive no benefit from the surgical procedure. The amount of residual disease after cytoreductive surgery has been repeatedly identifie...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-015-0439-z
更新日期：2015-04-01 00:00:00
abstract：:Primary and metastatic spinal mesenchymal tumors are uncommon lesions. Surgical management of these tumors remains a challenge. En bloc wide resection provides the best chance for local tumor control and long-term survival. However, limitations to this technique include technical considerations (including neurovascula...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0036-2
更新日期：2006-07-01 00:00:00
abstract：:Postmastectomy radiotherapy continues to be one of the most controversial issues in breast radiotherapy. At the crux of the controversy lies the lack of conclusive studies that specifically address the risk-benefit ratio of postmastectomy radiotherapy for patients at intermediate risk of developing locoregional recurr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0006-8
更新日期：2006-01-01 00:00:00
abstract：:The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inh...
journal_title：Current oncology reports
pub_type： 杂志文章
doi：10.1007/s11912-006-0045-1
更新日期：2006-03-01 00:00:00
abstract：:High-grade serous ovarian carcinoma (HGSOC) accounts for the majority of the ovarian cancer deaths, but over the last years little improvement in overall survival has been achieved. HGSOC is a molecularly and clinically heterogeneous disease. At genomic level, it represents a C-class malignancy having frequent gene lo...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0526-9
更新日期：2016-07-01 00:00:00
abstract：PURPOSE OF REVIEW:Over the past two decades, advances have been made in understanding the pathophysiology of cancer-associated weight loss, termed "cachexia." To date, there is no proven effective intervention to completely reverse cachexia and there are no approved drug therapies to treat it. This paper will review re...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-019-0765-7
更新日期：2019-02-04 00:00:00
abstract：PURPOSE OF REVIEW:Surgical management of locally advanced oral cavity squamous cell carcinomas (OCSCC) has long been recognized as a primary treatment modality. Technological advances have led to significant improvements in our surgical approach, from improvement in the visualization of tumors to more efficient and pre...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-019-0845-8
更新日期：2019-11-07 00:00:00
abstract：PURPOSE OF REVIEW:Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. RECENT FINDI...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00969-w
更新日期：2020-08-15 00:00:00
abstract：:Intensity-modulated radiotherapy (IMRT) is the next evolutionary step of three-dimensional conformal radiotherapy (3-DCRT). IMRT plans are generated with computer-optimized nonuniform radiation beam intensities incident on a target or patient. The dose distributions in IMRT show significantly higher conformality compa...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-003-0100-0
更新日期：2003-03-01 00:00:00
abstract：PURPOSE OF REVIEW:The knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to therapeutic intervention strategies. Immune system optimization is a critical...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0625-2
更新日期：2017-08-12 00:00:00
abstract：PURPOSE OF REVIEW:Medical decisions concerning active surveillance are complex, especially when evidence on superiority of one of the treatments is lacking. Decision aids have been developed to facilitate shared decision-making on whether to pursue an active surveillance strategy. However, it is unclear how these decis...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00962-3
更新日期：2020-07-28 00:00:00
abstract：:Overall survival for patients with squamous cell carcinoma of the head and neck (SCCHN) has not improved appreciably over the past few decades. Because standard treatments have not controlled this disease with sufficiently high success rates, novel therapeutic approaches, such as immunotherapy, are under investigation...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0025-8
更新日期：2008-03-01 00:00:00
abstract：:The original version of this article, which published in Current Oncology Reports, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer. ...
journal_title：Current oncology reports
pub_type： 已发布勘误
doi：10.1007/s11912-019-0813-3
更新日期：2019-05-17 00:00:00
abstract：PURPOSE OF REVIEW:Treatment failure, in the form of either persistence or local recurrence, occurs in 10 to 30% of nasopharyngeal carcinoma patients after initial radiotherapy (RT). Early detection of persistent or recurrent disease aids in the recognition of tumors that can be candidates for salvage nasophayngectomy o...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00949-0
更新日期：2020-07-09 00:00:00
abstract：:Concurrent radiation therapy and chemotherapy is the primary treatment for patients with squamous cell tumors of the anal canal, and is also employed in the neoadjuvant setting for patients with stage II and III adenocarcinoma of the rectum. There is constant clinical study involving modifications of chemoradiotherapy...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0166-z
更新日期：2011-06-01 00:00:00
abstract：:The identification of somatic driver mutations in human samples has allowed for the development of a molecular classification for melanoma. Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-012-0249-5
更新日期：2012-10-01 00:00:00
abstract：PURPOSE OF REVIEW:Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0718-6
更新日期：2018-07-31 00:00:00
abstract：:Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0075-z
更新日期：2000-05-01 00:00:00
abstract：:The diagnosis of a gynecological malignancy during pregnancy is rare but not uncommon. Cancer treatment during pregnancy is possible, but both maternal and fetal interests need to be respected. Different treatment plans may be justifiable and multidisciplinary treatment is advised. Clinical trials are virtually imposs...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-014-0415-z
更新日期：2014-12-01 00:00:00
abstract：:Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcoma, and most feature abnormalities in two genes encoding the receptor tyrosine kinases (RTKs), KIT, and PDGFRA. The RTK inhibitor imatinib revolutionized treatment in GIST; however, drug resistance remains a challenge. Constitutive autophosph...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0316-6
更新日期：2013-08-01 00:00:00
abstract：:The topoisomerase I inhibitors such as irinotecan and topotecan are active agents against small-cell lung cancer that are effective in treating not only chemotherapy-naïve tumors but also progressed-stage tumors after treatment with cisplatin-based regimens, because their mechanism of antitumor activity differs from t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-001-0018-3
更新日期：2001-03-01 00:00:00
